scholarly journals A possible effect of montelukast on neurological aging examined by the use of register data

2020 ◽  
Author(s):  
Bjørn Grinde ◽  
Henrik Schirmer ◽  
Anne Elise Eggen ◽  
Ludwig Aigner ◽  
Bo Engdahl
Keyword(s):  
Brain Function ◽  
Register Data ◽  
Prescription Database ◽  
Test Results ◽  
Leukotriene Receptor Antagonist ◽  
Subjective Memory ◽  
Multivariate Test ◽  
Norwegian Prescription Database ◽  
Neurological Functioning ◽  
Leukotriene Receptor

Abstract Background The leukotriene receptor antagonist montelukast has been shown to rejuvenate aged brains in rats; however, data on humans are still scarce. Objective To investigate if montelukast may alleviate degenerative neurological changes using a register data. Setting Norwegian registry data analyses. Method The present observational study was based on data from the Norwegian Prescription Database and the Tromsø Study. The former has information regarding the use of prescription medicine; the latter includes tests for brain function such as subjective memory and finger-tapping. Multivariate linear regression analyses were performed to see how the use of various medications correlated with the test results, correcting for likely confounders. Main outcome measure Results on seven different tests considered relevant for neurological health were used as outcome. Results Previous use of montelukast correlated with improved scores on cognitive or neurological functioning (F = 2.20, p = 0.03 in a multivariate test). A range of other medications were tested with the same algorithm, including drugs acting on the immune system, but none of them correlated with (overall) significantly improved test results. Conclusion The present data suggest that montelukast may alleviate degenerative neurological changes associated with human aging.

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

2015 ◽  
Vol 5 (3) ◽  
Author(s):  
Laxman Devkota ◽  
Bhupendra Poudel ◽  
Junu Silwal
Keyword(s):  
In Vitro Release ◽  
Magnesium Stearate ◽  
Physical Parameters ◽  
Artificial Sweetener ◽  
Leukotriene Receptor Antagonist ◽  
Montelukast Sodium ◽  
Chewable Tablets ◽  
Leukotriene Receptor ◽  
Vitro Release

The objective of the present study is to develop chewable tablets containing different pharmaceutical compositions with simple manufacturing procedures using different excipients. Mannitols, L-HPC 11, Aspartame, Crospovidone, Crospovidone, Aerosil, and Magnesium Stearate are used as excipients for effective formulation of anti-asthmatic drug Montelukast. Montelukast is a selective, orally acting leukotriene receptor antagonist that is used for the treatment of asthma and seasonal allergic rhinitis. Montelukast chewable tablets were prepared by Direct Compression methods using suitable excipients. The chewable tablets were better presented using artificial sweetener Aspartame as flavouring agent. A total of forteen formulations were prepared and the granules were evaluated for pre-compression parameters. The formulated tablets were evaluated for post-compression parameters .The results showed that all the physical parameters were within the acceptable limits. The in vitro release study of all the formulations showed good release. The study concludes that aforementioned excipients can be used to design chewable montelukast sodium tablets.

Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction

1999 ◽  
Vol 43 (3) ◽  
pp. 185-186
Author(s):  
JONATHAN A. LEFF ◽  
WILLIAM W. BUSSE ◽  
DAVID PEARLMAN ◽  
EDWIN A. BRONSKY ◽  
JAMES KEMP ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Mild Asthma ◽  
Leukotriene Receptor Antagonist ◽  
Leukotriene Receptor ◽  
Exercise Induced

scholarly journals Effect of the leukotriene receptor antagonist ONO-1078 on extravascular lung water after coronary ligation in dogs.

1993 ◽  
Vol 57 (2) ◽  
pp. 161-166 ◽  
Author(s):  
HIROYA TANIGUCHI ◽  
YASUO TAKAYAMA ◽  
TOSHIJI IWASAKA ◽  
TERUHIRO TAMURA ◽  
HIROFUMI TAKASHIMA ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Extravascular Lung Water ◽  
Leukotriene Receptor Antagonist ◽  
Lung Water ◽  
Coronary Ligation ◽  
Leukotriene Receptor

Delayed Onset of Neuropsychiatric Effects Associated with Montelukast

2012 ◽  
Vol 29 (2) ◽  
pp. 125-127 ◽  
Author(s):  
Fintan Byrne ◽  
Bolarinwa Oluwole ◽  
Vanessa Whyte ◽  
Sabina Fahy ◽  
Delia McGuinness
Keyword(s):  
Complete Resolution ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Leukotriene Receptor Antagonist ◽  
Surveillance Studies ◽  
Delayed Onset ◽  
Increased Risk ◽  
Post Marketing ◽  
Leukotriene Receptor ◽  
Psychological Trigger

AbstractMontelukast (a leukotriene receptor antagonist) is a commonly prescribed medication used in the management of asthma in both children and adults. It has been associated with a possible increased risk of various neuropsychiatric events in post-marketing analyses of clinical trial data and surveillance studies. When establishing a link between a medication and side effects, it is usual to establish and enquire whether there is a chronological relationship between the commencement of the medication and the onset of the symptoms.We report a case where a number of unusual neuropsychiatric events were reported several years after commencement of montelukast in a young boy who may have a genetic predisposition and a likely psychological trigger. There was complete resolution of these symptoms upon the withdrawal of montelukast.

scholarly journals The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice

2021 ◽  
Vol 22 (5) ◽  
pp. 2782 ◽  
Author(s):  
Johanna Michael ◽  
Julia Zirknitzer ◽  
Michael Stefan Unger ◽  
Rodolphe Poupardin ◽  
Tanja Rieß ◽  
...  
Keyword(s):  
T Cells ◽  
Receptor Antagonist ◽  
Cd8 T Cells ◽  
Disease Model ◽  
Cognitive Outcome ◽  
Drug Candidate ◽  
Potential Drug ◽  
Leukotriene Receptor Antagonist ◽  
Leukotriene Receptor ◽  
5Xfad Mice

Alzheimer’s disease (AD) is the most common form of dementia. In particular, neuroinflammation, mediated by microglia cells but also through CD8+ T-cells, actively contributes to disease pathology. Leukotrienes are involved in neuroinflammation and in the pathological hallmarks of AD. In consequence, leukotriene signaling—more specifically, the leukotriene receptors—has been recognized as a potential drug target to ameliorate AD pathology. Here, we analyzed the effects of the leukotriene receptor antagonist montelukast (MTK) on hippocampal gene expression in 5xFAD mice, a commonly used transgenic AD mouse model. We identified glial activation and neuroinflammation as the main pathways modulated by MTK. The treatment increased the number of Tmem119+ microglia and downregulated genes related to AD-associated microglia and to lipid droplet-accumulating microglia, suggesting that the MTK treatment targets and modulates microglia phenotypes in the disease model compared to the vehicle. MTK treatment further reduced infiltration of CD8+T-cells into the brain parenchyma. Finally, MTK treatment resulted in improved cognitive functions. In summary, we provide a proof of concept for MTK to be a potential drug candidate for AD and provide novel modes of action via modulation of microglia and CD8+ T-cells. Of note, 5xFAD females showed a more severe pathology, and in consequence, MTK treatment had a more pronounced effect in the females compared to the males. The effects on neuroinflammation, i.e., microglia and CD8+ T-cells, as well as the effects on cognitive outcome, were dose-dependent, therefore arguing for the use of higher doses of MTK in AD clinical trials compared to the approved asthma dose.

Sign in / Sign up

Export Citation Format

Share Document